Intensity Therapeutics, Inc.
INTSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIntensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United. At a $11.9M market cap, Intensity Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Market Cap
$11.9M
Beta
3.05
P/E (TTM)
—
P/E (Fwd)
-1.63
EPS (TTM)
$-3.77
EPS (Fwd)
$-2.70
ROE
-207.4%
ROA
-90.4%
Cash
$10.2M
Total Debt
$102,000
Free CF
-$5.3M
52W Change
-42.7%
Annual Financials
Cash vs Debt
Where INTS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, INTS finished 29.22% below its 150-day moving average ($6.88) and 35.24% below its 200-day moving average ($7.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INTS overbought or oversold?
At the July 15, 2026 close, INTS's RSI(14) was 82.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intensity Therapeutics, Inc. holds $10.2M in cash against $102K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -207.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 3.05 means INTS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INTS.